2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Buy
55
ACAD Quote, Financials, Valuation and Earnings
Last price:
$17.35
Seasonality move
:
19.92%
Day range:
$16.71 - $17.70
52-week range:
$14.15 - $20.68
Dividend yield:
0%
P/E ratio:
12.87x
P/S ratio:
3.04x
P/B ratio:
3.98x
Volume:
2M
Avg. volume:
1.7M
1-year change:
-6.57%
Market cap:
$2.9B
Revenue:
$957.8M
EPS (TTM):
$1.36
Analysts' Opinion
-
Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Hold. The company's average rating is a Hold based on 6 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $24.85, ACADIA Pharmaceuticals has an estimated upside of 42% from its current price of $17.50.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.00 representing 100% downside risk from its current price of $17.50.
Fair Value
-
According to the consensus of 13 analysts, ACADIA Pharmaceuticals has 42% upside to fair value with a price target of $24.85 per share.
ACAD vs. S&P 500
-
Over the past 5 trading days, ACADIA Pharmaceuticals has overperformed the S&P 500 by 1.98% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
ACADIA Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ACADIA Pharmaceuticals has grown year-over-year revenues for 9 quarters straight. In the most recent quarter ACADIA Pharmaceuticals reported revenues of $259.6M.
Earnings Growth
-
ACADIA Pharmaceuticals has grown year-over-year earnings for 1 quarter straight. In the most recent quarter ACADIA Pharmaceuticals reported earnings per share of $0.86.
Enterprise value:
2.2B
EV / Invested capital:
2.95x
Price / LTM sales:
3.04x
EV / EBIT:
25.66x
EV / Revenue:
2.26x
PEG ratio (5yr expected):
--
EV / Free cash flow:
13.76x
Price / Operating cash flow:
18.54x
Enterprise value / EBITDA:
21.59x
Gross Profit (TTM):
$876M
Return On Assets:
24.18%
Net Income Margin (TTM):
23.64%
Return On Equity:
41.59%
Return On Invested Capital:
41.59%
Operating Margin:
2.69%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $517.2M | $726.4M | $957.8M | $231M | $259.6M | |
| Gross Profit | $507.1M | $684.8M | $876M | $213.2M | $237.8M | |
| Operating Income | -$223.6M | -$73.4M | $84.3M | $34.9M | $7M | |
| EBITDA | -$221.6M | -$67.8M | $100.2M | $36.6M | $12.2M | |
| Diluted EPS | -$1.34 | -$0.38 | $1.36 | $0.28 | $0.86 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $717.6M | $617.8M | $507.9M | $616.1M | $938.3M | |
| Total Assets | $782.6M | $700.1M | $587.8M | $749M | $1.2B | |
| Current Liabilities | $106M | $96.1M | $125.6M | $254.3M | $394.9M | |
| Total Liabilities | $155.6M | $159.2M | $187.4M | $317.2M | $455M | |
| Total Equity | $627M | $540.9M | $400.4M | $431.8M | $732.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$114M | $16.7M | $157.7M | $85.4M | $40.4M | |
| Cash From Investing | $73.2M | $32M | -$30.5M | -$347K | $122.2M | |
| Cash From Financing | $8.2M | $25.1M | $6.8M | $5.4M | $2M | |
| Free Cash Flow | -$114M | -$23.3M | $157.2M | $85.4M | $39.9M | |
ACAD
Sector
Market Cap
$2.9B
$37.4M
Price % of 52-Week High
84.62%
45.61%
Dividend Yield
0%
0%
Shareholder Yield
-0.22%
-0.75%
1-Year Price Total Return
-6.57%
-38.36%
Beta (5-Year)
0.426
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$17.47
200-day SMA
Buy
Level
$16.74
Bollinger Bands (100)
Buy
Level
15.87 - 18.83
Chaikin Money Flow
Buy
Level
7.9M
20-day SMA
Sell
Level
$18.67
Relative Strength Index (RSI14)
Sell
Level
42.68
ADX Line
Sell
Level
17.14
Williams %R
Neutral
Level
-77.4194
50-day SMA
Sell
Level
$18.35
MACD (12, 26)
Sell
Level
-0.42
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
259M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.0256)
Buy
CA Score
(Annual)
Level (0.7808)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-3.0503)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Stock Forecast FAQ
In the current month, ACAD has received 6 Buy ratings 7 Hold ratings, and 0 Sell ratings. The ACAD average analyst price target in the past 3 months is $24.85.
-
Where Will ACADIA Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that ACADIA Pharmaceuticals share price will rise to $24.85 per share over the next 12 months.
-
What Do Analysts Say About ACADIA Pharmaceuticals?
Analysts are divided on their view about ACADIA Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ACADIA Pharmaceuticals is a Sell and believe this share price will drop from its current level to $11.00.
-
What Is ACADIA Pharmaceuticals's Price Target?
The price target for ACADIA Pharmaceuticals over the next 1-year time period is forecast to be $24.85 according to 13 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is ACAD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ACADIA Pharmaceuticals is a Hold. 7 of 13 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of ACAD?
You can purchase shares of ACADIA Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ACADIA Pharmaceuticals shares.
-
What Is The ACADIA Pharmaceuticals Share Price Today?
ACADIA Pharmaceuticals was last trading at $17.35 per share. This represents the most recent stock quote for ACADIA Pharmaceuticals. Yesterday, ACADIA Pharmaceuticals closed at $17.50 per share.
-
How To Buy ACADIA Pharmaceuticals Stock Online?
In order to purchase ACADIA Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Ford Stock Undervalued Amid the EV Transition?
There is a lot going on in the electric vehicle…
Is Goldman Sachs Stock a Buy Sell or Hold?
When the Federal Reserve started hiking rates in 2022, banks’…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
49
SMTC alert for Mar 17
Semtech [SMTC] is down 0.49% over the past day.
Buy
62
PLPC alert for Mar 17
Preformed Line Products [PLPC] is up 3.8% over the past day.
Sell
50
NUTX alert for Mar 17
Nutex Health [NUTX] is up 4.82% over the past day.
